Antigen-Dependent Internalization Is Related to Rapid Elimination from Plasma of Humanized Anti-HM1.24 Monoclonal Antibody

Abstract

ABSTRACT:Anti-HM1.24 monoclonal antibody (AHM) is a humanized anti-HM1.24 monoclonal antibody that binds to the HM1.24 antigen, a protein that is highly expressed in multiple myeloma cells. The pharmacokinetics of AHM was determined in experiments in which AHM was administered intravenously to cynomolgus monkeys. The area under the plasma concentration-time curve increased by more than the dose ratio between 2 and 20 mg/kg, and nonlinear pharmacokinetics was observed. The elimination half-life of AHM from the plasma was 7.56 h at 2 mg/kg and 28.6 h at 20 mg/kg, which was shorter than that observed for other therapeutic humanized monoclonal antibodies, such as trastuzumab and bevacizumab. Although antibodies to AHM were detected in all monkeys on or after 10 days of administration, there was a temporal disassociation between the rapid elimination of AHM and the appearance of anti-AHM antibodies. HM1.24 antigendependent internalization and intracellular metabolism of AHM were investigated in peripheral blood mononuclear, KPMM2, and U937 cells. In all cases, AHM was rapidly internalized from the cell surface; this internalization was significantly prevented by phenylarsine oxide in KPMM2 cells, an inhibitor of receptor-mediated endocytosis, and the internalized AHM was subsequently degraded within the cells. Furthermore, immunofluorescence microscopy revealed that the internalized AHM is delivered to and degraded in late endosomes/ lysosomes. Taken together, our results suggest that the rapid elimination of AHM from plasma in monkey is due to HM1.24 antigendependent internalization followed by delivery to the lysosomes.

Correlation of Sprouty1 and Jagged1 With Aggressive Prostate Cancer Cells With Different Sensitivities to Androgen Deprivation

“…6D). N-cadherin is reported to be associated with prostate cancer invasion or metastasis [Amano et al, 2010]. The N-cadherin expression levels in LNCaP-cl5 were higher than in LNCaP-cl1, correlating with the JAG1 expression levels.…”

Pharmacokinetic comparison of a diverse panel of non-targeting human antibodies as matched IgG1 and IgG2 isotypes in rodents and non-human primates

“…Human IgG1 antibodies are frequently employed as human therapeutics, whereas human IgG2, IgG4 [1] and other antibody subclasses are less commonly used [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]. While rodents are heavily utilized for pharmacokinetic (PK) assessment of antibodies, non-human primates, most commonly NHPs, are generally regarded as the better predictors of human pharmacokinetics for these molecules [11].…”

Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells

“…The extracellular domain bears two N-linked glycosylation sites, and the C-terminus is modified with a glycosylphosphatidylinositol (GPI) membrane anchor. In addition, HM1.24 is a lipid raft-associated glycoprotein traversing between the cell surface and the Golgi apparatus [23–25]. …”